Td Asset Management Inc Mersana Therapeutics, Inc. Transaction History

Td Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$5.48 - $9.86 $246,912 - $444,262	-45,057 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$8.56 - $14.47 $247,358 - $418,139	-28,897 Reduced 39.07%	45,057 $425,000
Q2 2021 Aug 11, 2021	SELL	$13.28 - $18.07 $177,991 - $242,192	-13,403 Reduced 15.34%	73,954 $813,000
Q1 2021 May 14, 2021	SELL	$15.31 - $26.52 $37,233 - $64,496	-2,432 Reduced 2.71%	87,357 $1.41 Million
Q4 2020 Feb 16, 2021	BUY	$16.84 - $27.59 $555,720 - $910,470	33,000 Added 58.11%	89,789 $2.39 Million
Q3 2020 Nov 10, 2020	BUY	$16.2 - $25.7 $541,080 - $858,380	33,400 Added 142.8%	56,789 $1.06 Million
Q2 2020 Aug 13, 2020	BUY	$5.24 - $23.4 $122,558 - $547,302	23,389 New	23,389 $547,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.